Dogwood Therapeutics, Inc. Regains Nasdaq Compliance
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biopharmaceutical company focused on...
Month: April 2025
Ernexa Therapeutics Closes New Funding Round
Comes on the heels of company’s rebranding and new strategic direction, advancing its lead program in ovarian cancerCAMBRIDGE, Mass., April...
Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to...
Globus Medical completes acquisition of Nevro Corp.
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the...
NewGen Secures Strategic Funding to Drive International Expansion and Corporate Growth
Initial focus includes NewGen’s expansion into UAE, with further growth initiatives to followBANGKOK, April 03, 2025 (GLOBE NEWSWIRE) -- NewGenIvf...
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...
Bemax Inc. Announces Updates on Special Dividend Distribution
Dallas, Georgia--(Newsfile Corp. - April 3, 2025) - Bemax Inc. (OTC Pink: BMXC), a private label development company with a...
Scienture Holdings, Inc. Issues Annual Letter to Shareholders
TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned...
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study DataRUTHERFORD, N.J. and...
Elutia to Participate in Upcoming Investor Conferences
SILVER SPRING, Md., April 03, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies,...
Phathom Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing...
BetterLife Pharma Appoints Corporate Advisor
VANCOUVER, British Columbia, April 03, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB...
Neurona Therapeutics Raises $102 Million to Fuel NRTX-1001 Phase 3 EPIC Epilepsy Trial and Advance Regenerative Cell Therapy Pipeline
- The oversubscribed private financing round, with primary participation from Fidelity Management & Research Company, The Column Group, Soleus Capital,...
Cingulate Completes Pre-NDA Meeting with FDA to Discuss New Drug Application for lead ADHD Asset CTx-1301
NDA Submission On-Target for Mid-2025KANSAS CITY, Kan., April 03, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing...
NeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual Meeting
Three-year data from NeuroPace’s Post-Approval Study of the RNS® System in drug-resistant focal epilepsy to be shared in oral presentationMOUNTAIN...
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to...
Extendicare Announces Timing of 2025 First Quarter Results and Conference Call
MARKHAM, Ontario, April 03, 2025 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced today that it...
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
CAMBRIDGE, Mass., April 03, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to...
Greenwich LifeSciences Provides Global Update on FLAMINGO-01
STAFFORD, Texas, April 03, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN
On track to announce primary endpoint result from ORIGIN 3 trial this quarter (2Q 2025)U.S. FDA BLA submission for accelerated...